The global T cell surface glycoprotein CD market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). CD is a glycoprotein that serves as a co-receptor for the T-cell receptor (TCR). CD4 is found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells. The major factor driving the demand for the global t cell surface glycoprotein CD4 market during the forecast period is the increasing prevalence of HIV across the globe.
According to the World Health Organization (WHO), an estimated 37.7 million people were living with HIV at the end of 2020. Additionally, out of these, over two-thirds of people or 25.4 million are in the WHO African Region. Further, in 2020, there was a mortality rate of 680,000 from HIV-related causes. Moreover, there were 1.5 million new cases of HIV in 2020. Apart from this, due to the viral envelope glycoprotein gp120 binding to CD4 with a high affinity, it functions as a receptor for human immunodeficiency virus type-I (HIV-1) and is used for HIV treatment. Hence, the increasing prevalence of HIV is driving the demand for t cell surface glycoprotein CD which in turn is driving the growth of the market.
To Request a Sample of our Report on T Cell Surface Glycoprotein CD Market: https://www.omrglobal.com/request-sample/t-cell-surface-glycoprotein-cd-market
Some major players in the market include Bristol-Myers Squibb Co., and Johnson and Johnson Services, Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2019, Bristol-Myers Squibb Company announced that it has submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for lisocabtagene maraleucel (liso-cel), its autologous anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy that comprises of individually formulated CD8+ and CD4+ CAR T cells. It is intended for the treatment of relapsed or refractory (R/R) large B-cell lymphoma (LBCL) in adult patients after at least two prior therapies.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Bristol-Myers Squibb Co., and Johnson and Johnson Services, Inc., among others.
(Get 15% Discount on Buying this Report)
A full Report of T Cell Surface Glycoprotein CD Market is Available @ https://www.omrglobal.com/industry-reports/t-cell-surface-glycoprotein-cd-market
Global T Cell Surface Glycoprotein CD Market Report by Segment
By Type
- CD3
- CD4
- CD5
- Others
By Application
- HIV
- AIDS
- GVHD
- SARS
- Cancer
- Others
Global T Cell Surface Glycoprotein CD Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
